None
Quote | Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)
Last: | $6.35 |
---|---|
Change Percent: | 0.0% |
Open: | $6.43 |
Close: | $6.35 |
High: | $6.82 |
Low: | $6.1242 |
Volume: | 5,711 |
Last Trade Date Time: | 09/27/2023 03:00:00 am |
News | Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting PR Newswire NORWOOD, Mass. , Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire NORWOOD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Corbus Phar...
Message Board Posts | Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)
Subject | By | Source | When |
---|---|---|---|
$CRBP Good news recently, we should start to see this one move | DollarDan | investorshub | 06/22/2023 8:32:35 AM |
$CRBP bears are running | glenn1919 | investorshub | 06/20/2023 6:44:44 PM |
$CRBP The now up | dinogreeves | investorshub | 06/19/2023 10:01:17 AM |
$CRBP Do we have a winner?Turn around time? | dfrank1988 | investorshub | 06/18/2023 10:45:01 AM |
must see | glenn1919 | investorshub | 06/17/2023 8:40:06 PM |
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting PR Newswire NORWOOD, Mass. , Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire NORWOOD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Corbus Phar...
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 P...